RiverFront Investment Group LLC Grows Stock Position in Eli Lilly and Company $LLY

RiverFront Investment Group LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 85.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,373 shares of the company’s stock after purchasing an additional 7,982 shares during the quarter. RiverFront Investment Group LLC’s holdings in Eli Lilly and Company were worth $13,543,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Financial Gravity Companies Inc. acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $31,000. Blume Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $35,000. Finally, TD Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research analyst reports. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. CICC Research lifted their price objective on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Loop Capital set a $950.00 target price on Eli Lilly and Company in a report on Monday, November 10th. Cantor Fitzgerald boosted their price objective on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, HSBC raised their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,047.50.

Eli Lilly and Company Stock Up 0.8%

Shares of NYSE:LLY opened at $1,067.68 on Tuesday. The company has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 69.78, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a 50 day moving average of $862.28 and a two-hundred day moving average of $790.04. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,075.72. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.